Q4 2024 13F Holders as of 31 Dec 2024
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
10,781,082
-
Number of holders
-
32
-
Total 13F shares, excl. options
-
2,499,825
-
Shares change
-
-48,838
-
Total reported value, excl. options
-
$7,996,845
-
Value change
-
-$160,960
-
Put/Call ratio
-
13%
-
Number of buys
-
10
-
Number of sells
-
-15
-
Price
-
$3.19
Significant Holders of Lantern Pharma Inc. - Common Stock, par value $0.0001 per share (LTRN) as of Q4 2024
39 filings reported holding LTRN - Lantern Pharma Inc. - Common Stock, par value $0.0001 per share as of Q4 2024.
Lantern Pharma Inc. - Common Stock, par value $0.0001 per share (LTRN) has 32 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 2,499,825 shares
of 10,781,082 outstanding shares and own 23% of the company stock.
Largest 10 shareholders include BIOS Capital Management, LP (1,207,709 shares), VANGUARD GROUP INC (363,720 shares), CM Management, LLC (200,000 shares), RENAISSANCE TECHNOLOGIES LLC (87,300 shares), GEODE CAPITAL MANAGEMENT, LLC (86,973 shares), NewEdge Advisors, LLC (68,359 shares), Voss Capital, LP (50,000 shares), BlackRock, Inc. (40,596 shares), CITADEL ADVISORS LLC (37,587 shares), and Redmond Asset Management, LLC (37,270 shares).
This table shows the top 32 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.